Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms

FASEB Journal

Volumn 31, Issue 4, 2017, Pages 1273-1288

  Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Leukocytes; Lipoxins; Maresins; Omega 3 PUFA; Protectins; Resolvins

Indexed keywords

ADRENOCHROME; ARACHIDONIC ACID; CD59 ANTIGEN; LIPID; LIPOXIN; MEDIATOR COMPLEX; OMEGA 3 FATTY ACID; ANTIINFLAMMATORY AGENT; AUTACOID;

CELL INVASION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASES; DRUG TARGETING; GENERAL SURGERY; HISTORY; HUMAN; INFECTION; INFLAMMATION; LIPID METABOLISM; MEDIATOR; METABOLOME; METABOLOMICS; MULTICENTER STUDY (TOPIC); NONHUMAN; PERSONALIZED MEDICINE; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SPECIALIZED PRORESOLVING MEDIATOR; TISSUE REGENERATION; ANIMAL; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; FATTY ACIDS, OMEGA-3; HUMANS; INFECTION; INFLAMMATION MEDIATORS;

EID: 85013862395     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201601222R     Document Type: Review

References (167)

1. Majno, G., and Joris, I. (2004) Cells, Tissues, and Disease: Principles of General Pathology, Oxford University Press, New York
2. Flower, R. J. (1985) Cyclooxygenase inhibitors: an overview. In Prostaglandins, Leukotrienes and Lipoxins: Biochemistry, Mechanism of Action, and Clinical Applications (Bailey, J. M., ed.), pp. 583-591, Plenum, New York
3. Koopman, W. J., and Moreland, L. W., eds. (2005) Arthritis and Allied Conditions: A Textbook of Rheumatology, LippincottWilliams&Wilkins, Philadelphia
4. Griffiths, R. J. (1999) Prostaglandins and inflammation. In Inflammation: Basic Principles and Clinical Correlates (Gallin, J. I., and Snyderman, R., eds.), pp. 349-360, Lippincott Williams & Wilkins, Philadelphia
5. Robbins, S. L., and Cotran, R. (1979) Pathologic Basis of Disease, W.B. Saunders Co., Philadelphia
6. Henson, P. M. (1991) Resolution of inflammation: a perspective. Chest 99(Suppl), 2S-6S
7. Savill, J. S., Wyllie, A. H., Henson, J. E., Walport, M. J., Henson, P. M., and Haslett, C. (1989)Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 83, 865-875
8. Serhan, C.N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204
9. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., and Moussignac, R.-L. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037
10. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., and Serhan, C. N. (2003) Novel docosatrienes and 17S-resolvins generatedfromdocosahexaenoic acidinmurinebrain, humanblood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687
11. Serhan, C. N. (2011)Theresolutionof inflammation: thedevil inthe flask and in the details. FASEB J. 25, 1441-1448
12. Serhan, C. N. (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101
13. Gilroy, D. W., Lawrence, T., Perretti, M., and Rossi, A. G. (2004) Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3, 401-416
14. Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D.W., Haslett, C., O'Neill, L. A. J., Perretti, M., Rossi, A. G., and Wallace, J. L. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332
15. Jones, H. R., Robb, C. T., Perretti, M., and Rossi, A. G. (2016) The role of neutrophils in inflammation resolution. Semin. Immunol. 28, 137-145
16. Perretti, M. (2015) The resolution of inflammation: new mechanisms in patho-physiology open opportunities for pharmacology. Semin. Immunol. 27, 145-148
17. Robb, C.T., Regan, K.H., Dorward, D.A., and Rossi, A.G. (2016)Key mechanisms governing resolution of lung inflammation. Semin. Immunopathol. 38, 425-448
18. Tabas, I., and Glass, C. K. (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166-172
19. Fullerton, J.N., and Gilroy, D.W. (2016) Resolution of inflammation: a new therapeutic frontier. Nat. Rev. Drug Discov. 15, 551-567
20. Buckley, C. D., Gilroy, D. W., and Serhan, C.N. (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315-327
21. Spite, M., Clària, J., and Serhan, C. N. (2014) Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 19, 21-36
22. Serhan, C. N., Dalli, J., Colas, R. A., Winkler, J. W., and Chiang, N. (2015) Protectins and maresins: new pro-resolving families of mediators in acute inflammationand resolutionbioactivemetabolome. Biochim. Biophys. Acta 1851, 397-413
23. Serhan, C. N., Chiang, N., and Dalli, J. (2015)The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin. Immunol. 27, 200-215
24. Dinarello, C. A. (2010) Anti-inflammatory agents: present and future. Cell 140, 935-950
25. Nathan, C. (2012) Fresh approaches to anti-infective therapies. Sci. Transl. Med. 4, 140sr2
26. Winyard, P. G., and Willoughby, D. A., eds (2003) Inflammation Protocols, Humana, Totowa, NJ, USA
27. Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., and Serhan, C. N. (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345-4355
28. Van Dyke, T. E. (2008) The management of inflammation in periodontal disease. J. Periodontol. 79(Suppl), 1601-1608
29. Serhan, C.N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S. P., Stahl, G.L., Merched, A., Petasis, N.A., Chan, L., and Van Dyke, T. E. (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171, 6856-6865
30. Van Dyke, T. E., Serhan, C. N. (2006) A novel approach to resolving inflammation. Sci. Am. Oral and Whole Body Health 2006, 42-45
31. Dalli, J., Ramon, S., Norris, P. C., Colas, R. A., and Serhan, C. N. (2015) Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways. FASEB J. 29, 2120-2136
32. Samuelsson, B. (1983) Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220, 568-575
33. Dalli, J., Chiang, N., and Serhan, C. N. (2015) Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat. Med. 21, 1071-1075
34. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., and Serhan, C. N. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619
35. Norris, P.C., Gosselin, D., Reichart, D., Glass, C.K., and Dennis, E.A. (2014) Phospholipase A2 regulates eicosanoid class switching during inflammasome activation. Proc. Natl. Acad. Sci. USA 111, 12746-12751
36. Maddox, J. F., and Serhan, C. N. (1996)LipoxinA4 andB4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183, 137-146
37. Jones, C.N., Dalli, J., Dimisko, L., Wong, E., Serhan, C.N., and Irimia, D. (2012) Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc. Natl. Acad. Sci. USA 109, 20560-20565
38. Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., and Brady, H. R. (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocytederived macrophages. J. Immunol. 164, 1663-1667
39. Börgeson, E., McGillicuddy, F. C., Harford, K. A., Corrigan, N., Higgins, D. F., Maderna, P., Roche, H. M., and Godson, C. (2012) Lipoxin A4 attenuates adipose inflammation. FASEB J. 26, 4287-4294
40. Martins, V., Valença, S. S., Farias-Filho, F. A., Molinaro, R., Simões, R. L., Ferreira, T. P.T., e Silva, P.M., Hogaboam, C.M., Kunkel, S. L., Fierro, I. M., Canetti, C., and Benjamim, C. F. (2009) ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J. Immunol. 182, 5374-5381
41. Qiu, W., Guo, K., Yi, L., Gong, Y., Huang, L., and Zhong, W. (2014) Resolvin E1 reduces hepatic fibrosis in mice with Schistosoma japonicum infection. Exp. Ther. Med. 7, 1481-1485
42. Qu, X., Zhang, X., Yao, J., Song, J., Nikolic-Paterson, D. J., and Li, J. (2012) Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J. Pathol. 228, 506-519
43. Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., and Spite, M. (2009) Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23
44. Dalli, J., Zhu, M., Vlasenko, N.A., Deng, B., Haeggström, J.Z., Petasis, N. A., and Serhan, C. N. (2013) The novel 13S, 14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 27, 2573-2583
45. Serhan, C. N., Dalli, J., Karamnov, S., Choi, A., Park, C. K., Xu, Z. Z., Ji, R. R., Zhu, M., and Petasis, N. A. (2012) Macrophage proresolving mediatormaresin1 stimulates tissue regenerationandcontrols pain. FASEB J. 26, 1755-1765
46. Levy, B. D., and Serhan, C. N. (2014) Resolution of acute inflammation in the lung. Annu. Rev. Physiol. 76, 27.21-27.26
47. Schwab, J. M., Chiang, N., Arita, M., and Serhan, C. N. (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869-874
48. Chan, M.M.-Y., and Moore, A.R. (2010)Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 184, 6418-6426
49. Serhan, C. N., and Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197
50. Chiang, N., Fredman, G., Bäckhed, F., Oh, S. F., Vickery, T., Schmidt, B. A., and Serhan, C. N. (2012) Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524-528
51. Haas-Stapleton, E. J., Lu, Y., Hong, S., Arita, M., Favoreto, S., Nigam, S., Serhan, C. N., and Agabian, N. (2007) Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS One 2, e1316
52. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N. A., and Serhan, C. N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722
53. Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., and Serhan, C. N. (2011) Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569-581
54. Oh, S. F., Dona, M., Fredman, G., Krishnamoorthy, S., Irimia, D., and Serhan, C. N. (2012) Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 188, 4527-4534
55. Isobe, Y., Arita, M., Matsueda, S., Iwamoto, R., Fujihara, T., Nakanishi, H., Taguchi, R., Masuda, K., Sasaki, K., Urabe, D., Inoue, M., and Arai, H. (2012) Identification and structure determination of novel antiinflammatory mediator resolvin E3, 17, 18-dihydroxyeicosapentaenoic acid. J. Biol. Chem. 287, 10525-10534
56. Lands, W.E.M. (2005)Fish, Omega-3 andHuman Health, AOCS Press, Champaign, IL, USA
57. Bracco, U., and Deckelbaum, R. J., eds. (1992) Polyunsaturated Fatty Acids in Human Nutrition, Raven Press, New York
58. Serhan, C. N., and Petasis, N. A. (2011) Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922-5943
59. Mukherjee, P.K., Marcheselli, V. L., Serhan, C. N., and Bazan, N. G. (2004) Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 101, 8491-8496
60. Campbell, E. L., Serhan, C. N., and Colgan, S. P. (2011) Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. J. Immunol. 187, 3475-3481
61. Rius, B., Titos, E., Morán-Salvador, E., López-Vicario, C., García-Alonso, V., González-Périz, A., Arroyo, V., and Clària, J. (2014) Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J. 28, 836-848
62. Serhan, C. N., and Chiang, N. (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr. Opin. Pharmacol. 13, 632-640
63. Chiang, N., Dalli, J., Colas, R. A., and Serhan, C. N. (2015) Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J. Exp. Med. 212, 1203-1217
64. Cooray, S. N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A. J., Flower, R. J., and Perretti, M. (2013) Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. USA 110, 18232-18237
65. Filep, J. G. (2013) Biasing the lipoxin A4/formyl peptide receptor 2 pushes inflammatory resolution. Proc. Natl. Acad. Sci. USA 110, 18033-18034
66. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.-H., Yang, R., Petasis, N. A., and Serhan, C. N. (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107, 1660-1665
67. Norling, L. V., Dalli, J., Flower, R. J., Serhan, C. N., and Perretti, M. (2012) Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler. Thromb. Vasc. Biol. 32, 1970-1978
68. Devchand, P. R., Arita, M., Hong, S., Bannenberg, G., Moussignac, R.-L., Gronert, K., and Serhan, C. N. (2003) Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17, 652-659
69. Chiang, N., Shinohara, M., Dalli, J., Mirakaj, V., Kibi, M., Choi, A. M. K., and Serhan, C. N. (2013) Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J. Immunol. 190, 6378-6388
70. Biteman, B., Hassan, I.R., Walker, E., Leedom, A. J., Dunn, M., Seta, F., Laniado-Schwartzman, M., and Gronert, K. (2007) Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J. 21, 2257-2266
71. Jin, S.-W., Zhang, L., Lian, Q.-Q., Liu, D., Wu, P., Yao, S.-L., and Ye, D.-Y. (2007) Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth. Analg. 104, 369-377
72. Colas, R. A., Shinohara, M., Dalli, J., Chiang, N., and Serhan, C. N. (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307, C39-C54
73. Dalli, J., Colas, R. A., Quintana, C., Barragan-Bradford, D., Hurwitz, S., Levy, B. D., Choi, A. M., Serhan, C. N., and Baron, R. M. (2017) Humansepsis eicosanoid and pro-resolving lipid mediator temporal profiles: correlations with survival and clinical outcomes. Crit. Care Med. 45, 58-68
74. Arnardottir, H., Orr, S. K., Dalli, J., and Serhan, C.N. (2016)Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunol. 9, 757-766
75. Norling, L. V., Headland, S. E., Dalli, J., Arnardottir, H. H., Haworth, O., Jones, H. R., Irimia, D., Serhan, C. N., and Perretti, M. (2016) Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight 1, e85922
76. Barden, A. E., Moghaddami, M., Mas, E., Phillips, M., Cleland, L. G., and Mori, T. A. (2016) Specialised pro-resolving mediators of inflammation in inflammatory arthritis. Prostaglandins Leukot. Essent. Fatty Acids 107, 24-29
77. Keelan, J.A., Mas, E., D'Vaz, N., Dunstan, J.A., Li, S., Barden, A. E., Mark, P. J., Waddell, B. J., Prescott, S. L., and Mori, T. A. (2015) Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. Reproduction 149, 171-178
78. Jones, M. L., Mark, P. J., Keelan, J.A., Barden, A., Mas, E., Mori, T. A., and Waddell, B. J. (2013)Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J. LipidRes. 54, 2247-2254
79. Polus, A., Zapala, B., Razny, U., Gielicz, A., Kiec-Wilk, B., Malczewska-Malec, M., Sanak, M., Childs, C. E., Calder, P. C., and Dembinska-Kiec, A. (2016) Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim. Biophys. Acta 1861, 1746-1755
80. Mas, E., Barden, A., Burke, V., Beilin, L. J., Watts, G. F., Huang, R. C., Puddey, I. B., Irish, A. B., and Mori, T. A. (2015) A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin. Nutr.35, 331-336
81. Barden, A. E., Mas, E., and Mori, T. A. (2016) n-3 Fatty acid supplementation and proresolving mediators of inflammation. Curr. Opin. Lipidol. 27, 26-32
82. Le Faouder, P., Baillif, V., Spreadbury, I., Motta, J. P., Rousset, P., Chêne, G., Guigné, C., Tercé, F., Vanner, S., Vergnolle, N., Bertrand-Michel, J., Dubourdeau, M., and Cenac, N. (2013) LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 932, 123-133
83. Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., and Welty, F. K. (2016) Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30, 2792-2801
84. Sun, Y.-P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., and Serhan, C. N. (2007) Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282, 9323-9334
85. Kasuga, K., Yang, R., Porter, T. F., Agrawal, N., Petasis, N. A., Irimia, D., Toner, M., and Serhan, C. N. (2008) Rapid appearance of resolvin precursors in inflammatory exudates: novelmechanisms in resolution. J. Immunol. 181, 8677-8687
86. Leslie, M. (2015) Inflammation's stop signals. Science 347, 18-21
87. (2009) Resolvyx announces positive data from Phase 2 clinical trial of the reesolvin RX-10045 in patients with dry eye syndrome. Business Wire Retrieved January 9, 2017, from http://www.businesswire. com/news/home/20090824005320/en/resolvyxannounces- positive-data-phase-20090824005322-clinical
88. De Paiva, C. S., Schwartz, C. E., Gjörstrup, P., and Pflugfelder, S. C. (2012) Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in amurinemodel of dry eye. Cornea 31, 1299-1303
89. Gronert, K. (2010) Resolution, the grail for healthy ocular inflammation. Exp. Eye Res. 91, 478-485
90. Li, N., He, J., Schwartz, C.E., Gjorstrup, P., and Bazan, H.E. P. (2010) Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J. Ocul. Pharmacol. Ther. 26, 431-439
91. Erdinest, N., Ovadia, H., Kormas, R., and Solomon, A. (2014) Antiinflammatory effects of resolvin-D1 on human corneal epithelial cells: in vitro study. J. Inflamm. (Lond.) 11, 6
92. Li, D., Hodges, R.R., Jiao, J., Carozza, R. B., Shatos, M. A., Chiang, N., Serhan, C. N., and Dartt, D. A. (2013) Resolvin D1 and aspirintriggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol. 6, 1119-1130
93. Hodges, R. R., Li, D., Shatos, M. A., Bair, J.A., Lippestad, M., Serhan, C. N., and Dartt, D. A. (2016) Lipoxin A4 activates ALX/FPR2 receptor to regulate conjunctival goblet cell secretion. Mucosal Immunol. doi: 10.1038/mi.2016.33
94. Dartt, D. A., Hodges, R. R., Li, D., Shatos, M. A., Lashkari, K., and Serhan, C.N. (2011)Conjunctival goblet cell secretionstimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J. Immunol. 186, 4455-4466
95. Cortina, M. S., and Bazan, H. E. (2011) Docosahexaenoic acid, protectins and dry eye. Curr. Opin. Clin. Nutr. Metab. Care 14, 132-137
96. Gao, Y., Min, K., Zhang, Y., Su, J., Greenwood, M., and Gronert, K. (2015) Female-specific downregulation of tissue polymorphonuclear neutrophils drives impaired regulatory T cell and amplified effector T cell responses in autoimmune dry eye disease. J. Immunol. 195, 3086-3099
97. Wang, S. B., Hu, K. M., Seamon, K. J., Mani, V., Chen, Y., and Gronert, K. (2012) Estrogen negatively regulates epithelial wound healing and protective lipidmediator circuits in the cornea. FASEB J. 26, 1506-1516
98. Wu, S. H., Chen, X. Q., Liu, B., Wu, H. J., and Dong, L. (2013) Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br. J. Dermatol. 168, 172-178
99. Chiurchi u, V., Leuti, A., Dalli, J., Jacobsson, A., Battistini, L., Maccarrone, M., and Serhan, C. N. (2016) Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci. Transl. Med. 8, 353ra111
100. Ramon, S., Gao, F., Serhan, C. N., and Phipps, R. P. (2012) Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J. Immunol. 189, 1036-1042
101. Russell, C. D., and Schwarze, J. (2014) The role of pro-resolution lipid mediators in infectious disease. Immunology 141, 166-173
102. Dalli, J., Chiang, N., and Serhan, C. N. (2014) Identification of 14- series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proc. Natl. Acad. Sci. USA 111, E4753-E4761
103. Aursnes, M., Tungen, J. E., Colas, R. A., Vlasakov, I., Dalli, J., Serhan, C. N., and Hansen, T. V. (2015) Synthesis of the 16S, 17Sepoxyprotectin intermediate in the biosynthesis of protectins by human macrophages. J. Nat. Prod. 78, 2924-2931
104. Dalli, J., Vlasakov, I., Riley, I.R., Rodriguez, A.R., Spur, B.W., Petasis, N. A., Chiang, N., and Serhan, C. N. (2016) Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proc.Natl. Acad. Sci. USA 113, 12232-12237
105. Dalli, J., Sanger, J.M., Rodriguez, A. R., Chiang, N., Spur, B. W., and Serhan, C. N. (2016) Identification and actions of a novel third maresin conjugate in tissue regeneration: MCTR3. PLoS One 11, e0149319
106. Samuelsson, B., Dahlén, S. E., Lindgren, J. A., Rouzer, C. A., and Serhan, C. N. (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171-1176
107. Primdahl, K. G., Aursnes, M., Walker, M. E., Colas, R. A., Serhan, C.N., Dalli, J., Hansen, T. V., and Vik, A. (2016) Synthesis of 13(R)- hydroxy-7Z, 10Z, 13R, 14E, 16Z, 19Z docosapentaenoic acid (13RHDPA) and its biosynthetic conversion to the 13-series resolvins. J. Nat. Prod. 79, 2693-2702
108. Ramon, S., Dalli, J., Sanger, J. M., Winkler, J. W., Aursnes, M., Tungen, J. E., Hansen, T. V., and Serhan, C.N. (2016)Theprotectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation. Am. J. Pathol. 186, 962-973
109. Brezinski, D. A., Nesto, R.W., and Serhan, C. N. (1992) Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impactofaspirin therapy. Circulation 86, 56-63
110. Ho, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H., Pande, R., Creager, M. A., Serhan, C. N., and Conte, M. S. (2010) Aspirin-triggered lipoxin and resolvin E1modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am. J. Pathol. 177, 2116-2123
111. Libby, P., Tabas, I., Fredman, G., and Fisher, E. A. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114, 1867-1879
112. Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., Spite, M., and Tabas, I. (2016)Animbalance between specialized proresolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 7, 12859
113. Rathod, K. S., Kapil, V., Velmurugan, S., Khambata, R. S., Siddique, U., Khan, S., Van Eijl, S., Gee, L. C., Bansal, J., Pitrola, K., Shaw, C., D'Acquisto, F., Colas, R. A., Marelli-Berg, F., Dalli, J., and Ahluwalia, A. (2017) Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. J. Clin. Invest. 127, 169-182
114. Perretti, M., and D'Acquisto, F. (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 9, 62-70
115. Perretti, M., Leroy, X., Bland, E. J., and Montero-Melendez, T. (2015) Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol. Sci. 36, 737-755
116. Recchiuti, A., and Serhan, C.N. (2012) Pro-resolving lipidmediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation. Front. Immunol. 3, 298
117. Pierdomenico, A. M., Recchiuti, A., Simiele, F., Codagnone, M., Mari, V. C., Davì, G., and Romano, M. (2015) MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages. J. Biol. Chem. 290, 3592-3600
118. Luo, B., Wang, J., Liu, Z., Shen, Z., Shi, R., Liu, Y.Q., Liu, Y., Jiang, M., Wu, Y., and Zhang, Z. (2016) Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution. Nat. Commun. 7, 12177
119. Flannigan, K. L., Agbor, T. A., Motta, J. P., Ferraz, J. G., Wang, R., Buret, A. G., and Wallace, J. L. (2015) Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxiainducible factor-1a. FASEB J. 29, 1591-1602
120. Motta, J. P., Flannigan, K. L., Agbor, T. A., Beatty, J. K., Blackler, R. W., Workentine, M. L., Da Silva, G. J., Wang, R., Buret, A.G., and Wallace, J. L. (2015) Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm. Bowel Dis. 21, 1006-1017
121. Shinohara, M., Kibi, M., Riley, I. R., Chiang, N., Dalli, J., Kraft, B. D., Piantadosi, C. A., Choi, A. M., and Serhan, C. N. (2014) Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. Am. J. Physiol. Lung Cell. Mol. Physiol. 307, L746-L757
122. Dalli, J., Kraft, B. D., Colas, R. A., Shinohara, M., Fredenburgh, L. E., Hess, D.R., Chiang, N., Welty-Wolf, K., Choi, A.M., Piantadosi, C. A., and Serhan, C. N. (2015) The regulation of proresolving lipid mediator profiles in baboon pneumonia by inhaled carbon monoxide. Am. J. Respir. Cell Mol. Biol. 53, 314-325
123. Montanaro, G., Bertinaria, M., Rolando, B., Fruttero, R., Lucas, C. D., Dorward, D. A., Rossi, A. G., Megson, I. L., and Gasco, A. (2013) Novel R-roscovitine NO-donor hybrid compounds as potential proresolution of inflammation agents.Bioorg.Med. Chem. 21, 2107-2116
124. Rao, N.L., Dunford, P. J., Xue, X., Jiang, X., Lundeen, K.A., Coles, F., Riley, J. P., Williams, K.N., Grice, C. A., Edwards, J. P., Karlsson, L., and Fourie, A. M. (2007) Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J. Pharmacol. Exp. Ther. 321, 1154-1160
125. Basil, M. C., and Levy, B. D. (2016) Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 16, 51-67
126. El Kebir, D., Gjorstrup, P., and Filep, J. G. (2012) Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc.Natl. Acad. Sci. USA 109, 14983-14988
127. Felton, J. M., Lucas, C. D., Rossi, A. G., and Dransfield, I. (2014) Eosinophils in the lung: modulating apoptosis and efferocytosis in airway inflammation. Front. Immunol. 5, 302
128. Börgeson, E., and Godson, C. (2012) Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front. Immunol. 3, 318
129. Zhu, M., Wang, X., Schultzberg, M., and Hjorth, E. (2015) Differential regulation of resolution in inflammation induced by amyloid-b42 and lipopolysaccharides in human microglia. J. Alzheimers Dis. 43, 1237-1250
130. Harrison, J. L., Rowe, R. K., Ellis, T. W., Yee, N. S., O'Hara, B. F., Adelson, P. D., and Lifshitz, J. (2015) Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse. Brain Behav. Immun. 47, 131-140
131. Liu, G., Fiala, M., Mizwicki, M. T., Sayre, J., Magpantay, L., Siani, A., Mahanian, M., Chattopadhyay, M., La Cava, A., and Wiedau-Pazos, M. (2012) Neuronal phagocytosis by inflammatorymacrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis. 1, 60-74
132. Hasturk, H., Abdallah, R., Kantarci, A., Nguyen, D., Giordano, N., Hamilton, J., and Van Dyke, T. E. (2015) Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 35, 1123-1133
133. Kang, J.W., and Lee, S.M. (2016)ResolvinD1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarization and efferocytosis. Biochim. Biophys. Acta 1861(9 Pt A), 1025-1035
134. Fialkow, J. (2016)Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products. Am. J. Cardiovasc. Drugs 16, 229-239
135. Dalli, J., and Serhan, C. N. (2012) Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60-e72
136. Imai, Y. (2015) Role of omega-3 PUFA-derived mediators, the protectins, in influenza virus infection. Biochim. Biophys. Acta 1851, 496-502
137. Morris, T., Stables, M., Colville-Nash, P., Newson, J., Bellingan, G., de Souza, P.M., and Gilroy, D.W. (2010)Dichotomy indurationand severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc. Natl. Acad. Sci. USA 107, 8842-8847
138. Herrera, B. S., Hasturk, H., Kantarci, A., Freire, M. O., Nguyen, O., Kansal, S., and Van Dyke, T. E. (2015) Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect. Immun. 83, 792-801
139. Saito, T., Hasegawa-Moriyama, M., Kurimoto, T., Yamada, T., Inada, E., and Kanmura, Y. (2015) Resolution of inflammation by resolvin D1 is essential for peroxisome proliferator-activated receptorg- mediated analgesia during postincisional pain development in type 2 diabetes. Anesthesiology 123, 1420-1434
140. Shevalye, H., Yorek, M. S., Coppey, L. J., Holmes, A., Harper, M.M., Kardon, R. H., and Yorek, M. A. (2015) Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. J. Neurophysiol. 114, 199-208
141. Tang, Y., Zhang, M. J., Hellmann, J., Kosuri, M., Bhatnagar, A., and Spite, M. (2013) Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62, 618-627
142. Hellmann, J., Tang, Y., Kosuri, M., Bhatnagar, A., and Spite, M. (2011) Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 25, 2399-2407
143. Hong, S., Tian, H., Lu, Y., Laborde, J. M., Muhale, F. A., Wang, Q., Alapure, B. V., Serhan, C. N., and Bazan, N. G. (2014)Neuroprotectin/ protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes. Am. J. Physiol. Cell Physiol. 307, C1058-C1067
144. White, P. J., St-Pierre, P., Charbonneau, A., Mitchell, P.L., St-Amand, E., Marcotte, B., and Marette, A. (2014) Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis. Nat. Med. 20, 664-669
145. Salic, K., Morrison, M. C., Verschuren, L., Wielinga, P. Y., Wu, L., Kleemann, R., Gjorstrup, P., and Kooistra, T. (2016) Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250, 158-165
146. Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N., and Chan, L. (2008) Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595-3606
147. Viola, J. R., Lemnitzer, P., Jansen, Y., Csaba, G., Winter, C., Neideck, C., Silvestre-Roig, C., Dittmar, G., Döring, Y., Drechsler, M., Weber, C., Zimmer, R., Cenac, N., and Soehnlein, O. (2016) Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 119, 1030-1038
148. Hiram, R., Rizcallah, E., Sirois, C., Sirois, M., Morin, C., Fortin, S., and Rousseau, E. (2014) Resolvin D1 reverses reactivity and Ca2+ sensitivity induced by ET-1, TNF-a, and IL-6 in the human pulmonary artery. Am. J. Physiol. Heart Circ. Physiol. 307, H1547-H1558
149. Clària, J., Dalli, J., Yacoubian, S., Gao, F., and Serhan, C. N. (2012) Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J. Immunol. 189, 2597-2605
150. Titos, E., Rius, B., González-Périz, A., López-Vicario, C., Morán-Salvador, E., Martínez-Clemente, M., Arroyo, V., and Clària, J. (2011) Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward anM2-like phenotype. J. Immunol. 187, 5408-5418
151. González-Périz, A., Horrillo, R., Ferré, N., Gronert, K., Dong, B., Morán-Salvador, E., Titos, E., Martínez-Clemente, M., López-Parra, M., Arroyo, V., and Clària, J. (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946-1957
152. Neuhofer, A., Zeyda, M., Mascher, D., Itariu, B. K., Murano, I., Leitner, L., Hochbrugger, E. E., Fraisl, P., Cinti, S., Serhan, C.N., and Stulnig, T.M. (2013)Impairedlocalproductionofproresolvinglipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 62, 1945-1956
153. Sasaki, A., Fukuda, H., Shiida, N., Tanaka, N., Furugen, A., Ogura, J., Shuto, S., Mano, N., and Yamaguchi, H. (2015)Determinationofv-6 and v-3 PUFA metabolites in human urine samples using UPLC/ MS/MS (published correction in J. Immunol. 407, 2939-2940). Anal. Bioanal. Chem. 407, 1625-1639
154. Mas, E., Croft, K. D., Zahra, P., Barden, A., and Mori, T. A. (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58, 1476-1484
155. Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C., Bjorndahl, T. C., Krishnamurthy, R., Saleem, F., Liu, P., Dame, Z. T., Poelzer, J., Huynh, J., Yallou, F. S., Psychogios, N., Dong, E., Bogumil, R., Roehring, C., and Wishart, D. S. (2013) The human urine metabolome. PLoS One 8, e73076
156. Markworth, J. F., Vella, L., Lingard, B. S., Tull, D. L., Rupasinghe, T.W., Sinclair, A. J., Maddipati, K.R., andCameron-Smith, D. (2013) Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R1281-R1296
157. Weiss, G. A., Troxler, H., Klinke, G., Rogler, D., Braegger, C., and Hersberger, M. (2013) High levels of anti-inflammatory and proresolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels inhumanmilk during thefirstmonthof lactation. Lipids Health Dis. 12, 89
158. Yang, J., Eiserich, J. P., Cross, C. E., Morrissey, B.M., and Hammock, B. D. (2012)Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic. Biol. Med. 53, 160-171
159. Wang, X., Zhu, M., Hjorth, E., Cortés-Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., Fitzgerald, J. M., Serhan, C. N., Granholm, A.C., and Schultzberg, M. (2015) Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement. 11, 40-50.e1-e.2
160. Frediani, J. K., Jones, D. P., Tukvadze, N., Uppal, K., Sanikidze, E., Kipiani, M., Tran, V. T., Hebbar, G., Walker, D. I., Kempker, R. R., Kurani, S. S., Colas, R. A., Dalli, J., Tangpricha, V., Serhan, C. N., Blumberg, H.M., and Ziegler, T. R. (2014) Plasmametabolomics in human pulmonary tuberculosis disease: a pilot study. PLoS One 9, e108854
161. Arnardottir, H. H., Dalli, J., Norling, L. V., Colas, R. A., Perretti, M., and Serhan, C.N. (2016)ResolvinD3 is dysregulated in arthritis and reduces arthritic inflammation. J. Immunol. 197, 2362-2368
162. Mozurkewich, E. L., Greenwood, M., Clinton, C., Berman, D., Romero, V., Djuric, Z., Qualls, C., and Gronert, K. (2016) Pathway markers for pro-resolving lipid mediators inmaternal and umbilical cord blood: a secondary analysis of the Mothers, Omega-3, and Mental Health Study. Front. Pharmacol. 7, 274
163. Winkler, J.W., Orr, S. K., Dalli, J., Cheng, C. Y., Sanger, J.M., Chiang, N., Petasis, N. A., and Serhan, C. N. (2016) Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance. Sci. Rep. 6, 18972
164. Tungen, J. E., Aursnes, M., Vik, A., Ramon, S., Colas, R. A., Dalli, J., Serhan, C. N., and Hansen, T. V. (2014) Synthesis and antiinflammatory and pro-resolving activities of 22-OH-PD1, a monohydroxylated metabolite of protectin D1. J. Nat. Prod. 77, 2241-2247
165. Bazan, N. G., Eady, T.N., Khoutorova, L., Atkins, K.D., Hong, S., Lu, Y., Zhang, C., Jun, B., Obenaus, A., Fredman, G., Zhu, M., Winkler, J. W., Petasis, N. A., Serhan, C. N., and Belayev, L. (2012) Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp. Neurol. 236, 122-130
166. Serhan, C. N., Fredman, G., Yang, R., Karamnov, S., Belayev, L. S., Bazan, N. G., Zhu, M., Winkler, J. W., and Petasis, N. A. (2011)Novel proresolving aspirin-triggeredDHApathway. Chem. Biol. 18, 976-987
167. Tabas, I. (2016) Heart disease: death-defying plaque cells. Nature 536, 32-33